<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04756960</url>
  </required_header>
  <id_info>
    <org_study_id>CLI-06001AA1-02</org_study_id>
    <secondary_id>2020-004201-31</secondary_id>
    <nct_id>NCT04756960</nct_id>
  </id_info>
  <brief_title>Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast)</brief_title>
  <official_title>Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 Following a Single Inhaled Dose Co-administered With an Intravenous Radiolabelled Microtracer Dose in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the proposed study is to evaluate the bioavailability of CHF6001 after&#xD;
      inhaled administration and to characterize the mass balance and route of elimination of&#xD;
      CHF6001 in human along with its relevant metabolites.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is a single centre Phase I study, with a single dose, non-randomized,&#xD;
      open-label, uncontrolled design.&#xD;
&#xD;
      A total of 8 subjects will be included in the study.&#xD;
&#xD;
      It will aim to assess the absolute bioavailability, the mass balance and routes of&#xD;
      elimination of CHF6001 in male healthy volunteers, using [14C]-radiolabelled drug substance&#xD;
      administered as an intravenous (IV) infusion concomitantly to an inhaled non-radiolabelled&#xD;
      dose.&#xD;
&#xD;
      Standard safety assessments will be conducted during the Study, including safety blood and&#xD;
      urine laboratory tests, vital signs, physical examinations, ECGs and observations of any&#xD;
      adverse events. Blood, urine and feces samples will be also collected for PK analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 10, 2021</start_date>
  <completion_date type="Actual">April 29, 2021</completion_date>
  <primary_completion_date type="Actual">April 19, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameter (AUC0-t)</measure>
    <time_frame>Over 240 hours after administration</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC0-t) for [14C] CHF6001, [14C] total and CHF6001</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter (Cmax)</measure>
    <time_frame>Over 240 hours after administration</time_frame>
    <description>Peak Plasma Concentration (Cmax) for [14C] CHF6001, [14C] total and CHF6001</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter (tmax)</measure>
    <time_frame>Over 240 hours after administration</time_frame>
    <description>Time of the maximum plasma concentration (tmax) for [14C] CHF6001, [14C] total and CHF6001</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter (AUC0-∞)</measure>
    <time_frame>Over 240 hours after administration</time_frame>
    <description>Area under curve extrapolated to infinity (AUC0-∞) for [14C] CHF6001, [14C] total and CHF6001</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter (t1/2)</measure>
    <time_frame>Over 240 hours after administration</time_frame>
    <description>Terminal half-life (t1/2) for [14C] CHF6001, [14C] total and CHF6001</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter (volume of distribution)</measure>
    <time_frame>Over 240 hours after administration</time_frame>
    <description>Volume of distribution calculated at steady state and during the terminal phase for [14C] CHF6001</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter (clearance)</measure>
    <time_frame>Over 240 hours after administration</time_frame>
    <description>Systemic and renal blood and plasma clearance for [14C] CHF6001</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter (excreted fraction)</measure>
    <time_frame>Over 240 hours after administration</time_frame>
    <description>Urine and feces excreted fraction for [14C] CHF6001 and [14C] total</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter (fraction of metabolites)</measure>
    <time_frame>Over 240 hours after administration</time_frame>
    <description>Fraction of the relevant metabolites in plasma, and fraction of the relevant metabolites recovered in urine and feces</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter (blood to plasma ratio)</measure>
    <time_frame>Over 240 hours after administration</time_frame>
    <description>Blood to plasma ratio for [14C] CHF6001 and [14C] total</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter (Eh)</measure>
    <time_frame>Over 240 hours after administration</time_frame>
    <description>Hepatic extraction for [14C] CHF6001</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter (F)</measure>
    <time_frame>Over 240 hours after administration</time_frame>
    <description>Absolute inhaled bioavailability for CHF6001</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>CHF6001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of CHF6001 DPI co-administered with an intravenous microdose of [14C]-labelled CHF6001</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF6001</intervention_name>
    <description>4 inhalations of CHF6001 800µg/20mg NEXThaler® DPI (total dose of 3200µg) co-administered with an intravenous microdose (18.5µg (18.5kBq)) of [14C]-labelled CHF6001</description>
    <arm_group_label>CHF6001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject's written informed consent obtained prior to any study-related procedure;&#xD;
&#xD;
          2. Able to understand the study procedures, the risks involved and ability to be trained&#xD;
             to use correctly the inhalers and to generate sufficient PIF using the In-Check device&#xD;
             and Placebo inhaler;&#xD;
&#xD;
          3. Male subjects aged 30 to 55 years inclusive;&#xD;
&#xD;
          4. Body mass index (BMI) within the range of 18 to 35 kg/m2 inclusive;&#xD;
&#xD;
          5. Non- or ex-smoker who smoked &lt; 5 pack years and who stopped smoking &gt; 1 year prior to&#xD;
             screening;&#xD;
&#xD;
          6. Good physical and mental status;&#xD;
&#xD;
          7. Vital signs at screening within limits;&#xD;
&#xD;
          8. 12-lead digitised Electrocardiogram (12-lead ECG) in triplicate considered as normal;&#xD;
&#xD;
          9. Lung function measurements within normal limits at screening;&#xD;
&#xD;
         10. Regular bowel movements at screening;&#xD;
&#xD;
         11. Males with non-pregnant Women of Childbearing Potential (WOCBP) partners: they and/or&#xD;
             their partner of childbearing potential must be willing to use a highly effective&#xD;
             birth control method in addition to the male condom from the signature of the informed&#xD;
             consent and until 90 days after the follow-up visit. Males with pregnant WOCBP&#xD;
             partner: they must be willing to use male contraception (condom) from the signature of&#xD;
             the informed consent and until 90 days after the follow-up visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in another clinical trial with an investigational drug in the 3 months&#xD;
             or 5 half-lives of that investigational drug (whichever is longer) preceding the&#xD;
             administration of the study drug;&#xD;
&#xD;
          2. Clinically relevant and uncontrolled respiratory, cardiac, hepatic (including Gilbert&#xD;
             syndrome), gastrointestinal, renal, endocrine, metabolic, neurologic, or psychiatric&#xD;
             disorder;&#xD;
&#xD;
          3. Clinically relevant abnormal laboratory values;&#xD;
&#xD;
          4. Subjects with history of breathing problems;&#xD;
&#xD;
          5. Positive to HIV1 or HIV2 serology at screening;&#xD;
&#xD;
          6. Positive results from the Hepatitis serology which indicates acute or chronic&#xD;
             Hepatitis B or Hepatitis C at screening;&#xD;
&#xD;
          7. Blood donation or blood loss (equal or more than 450 mL) less than 2 months prior&#xD;
             screening or prior to treatment;&#xD;
&#xD;
          8. Positive urine test for cotinine;&#xD;
&#xD;
          9. Documented history of alcohol abuse within 12 months prior to screening or a positive&#xD;
             alcohol breath test;&#xD;
&#xD;
         10. Documented history of drug abuse within 12 months prior to screening or a positive&#xD;
             urine drug screen;&#xD;
&#xD;
         11. Intake of non-permitted concomitant medications in the predefined period;&#xD;
&#xD;
         12. Presence of any current infection, or previous infection that resolved less than 7&#xD;
             days prior to screening or before treatment;&#xD;
&#xD;
         13. Known intolerance and/or hypersensitivity to any of the excipients contained in the&#xD;
             formulation used in the trial;&#xD;
&#xD;
         14. Unsuitable veins for repeated venipuncture;&#xD;
&#xD;
         15. Heavy caffeine drinker;&#xD;
&#xD;
         16. Abnormal haemoglobin level at screening;&#xD;
&#xD;
         17. Subjects using e-cigarettes within 6 months prior to screening;&#xD;
&#xD;
         18. Subjects been involved in a study involving a 14C-labeled drug within the 12 months&#xD;
             prior to enrollment;&#xD;
&#xD;
         19. Subjects with exposure to significant diagnostic or therapeutic radiation or current&#xD;
             employment in a job requiring radiation exposure monitoring within 12 months prior to&#xD;
             Day-1;&#xD;
&#xD;
         20. Documented COVID-19 diagnosis within the last 8 weeks or which has not resolved within&#xD;
             14 days prior to screening and before treatment.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Covance - Clinical Research Unit</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

